Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation

Bucharest 022328

0 studies enrolling now · 2 studies all time

What they study most

DLBCL Transformed From Indolent Lymphoma, Diffuse Large B-cell Lymphoma, Disease, Hodgkin, Follicular Grade 3 Lymphoma, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, de Novo DLBCL

Studies at this site

• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant — Completed
• A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 — NO_LONGER_AVAILABLE